Healthcare Providers and Services
Company Overview of University Hospitals Cleveland Medical Center Inc.
University Hospitals Cleveland Medical Center Inc., doing business as University Hospitals Case Medical Center, owns and operates a tertiary medical center specializing in adult/pediatric medical and surgical specialties. Its services include cancer care, digestive health care, heart and vascular care, neurology and neurosurgery, obstetrics and gynecology, ophthalmology and dermatology, orthopedics and spine, otolaryngology, pediatrics, surgery, transplant, and urology. The company also provides services in the areas of women’s health, radiology and radiation oncology, cardiology and cardiothoracic surgery, organ transplantation and infectious diseases, behavioral health, and human genetics ...
11100 Euclid Avenue
Cleveland, OH 44106
Founded in 1866
Key Executives for University Hospitals Cleveland Medical Center Inc.
President and Chief of Cardiovascular Medicine
President of The UH Seidman Cancer Center
Chairman of the Department of Pediatrics at Rainbow Babies & Children's Hospital
Compensation as of Fiscal Year 2017.
University Hospitals Cleveland Medical Center Inc. Key Developments
Moleculin Biotech, Inc. Enters Agreement with The University Hospitals Cleveland Medical Center to Conduct Leukemia Clinical Trials
Mar 27 18
Moleculin Biotech Inc. announced that it has entered an agreement with The University Hospitals Cleveland Medical Center, which includes the Seidman Cancer Center and the Cleveland Clinic, to participate in its U.S. Phase I/II clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML) and that patient enrollment has begun.
UH Case Medical Center has Changed its Name to University Hospitals Cleveland Medical Center Inc
Sep 9 16
UH Case Medical Center changed its name to University Hospitals Cleveland Medical Center Inc.
University Hospitals Case Medical Center First to Implant Abbott Absorb Stent
Jul 8 16
University Hospitals Case Medical Center to offer and deploy the Abbott Absorb stent, a completely bioresorbable stent. The Absorb stent works exactly as its traditional metallic predecessors in that it opens a blocked coronary artery, with one major exception it dissolves completely in the body two to three years after implantation. University Hospitals (UH) implanted its first Absorb dissolving stent on a patient with coronary artery disease. Recently approved by the FDA, Absorb is the first and only fully dissolving stent approved for the treatment of coronary artery disease which impacts over 15 million people in the United States and is the cause of death. Made of naturally dissolving material, the new device provides the same benefits as traditional stents and trial data supports its potential benefits in restoring long-term vessel function. The stent utilizes the same cath lab equipment already in place and study data supports comparable healing with the traditional metallic stent. While it may never totally replace traditional DES, this novel technology gives the ability to repair a patient's artery with comparable healing and safety and reduces long-term complications. Like traditional metallic drug-eluding stents (DES), Absorb opens a patient's blocked artery but then disappears after leaving no metal behind to restrict natural vessel motion. Absorb is made of polyactic acid similar to material used in dissolving sutures. Through the process of hydrolysis, the scaffold is metabolized after two to three years. In clinical studies conducted throughout the world, the new Absorb stent demonstrated comparable short-term and mid-term outcomes compared to the metallic stent. After the first year of the clinical trial of approximately 2,000 patients in the United States (Absorb III randomized trial) patients who received the Absorb experienced comparable rates of specific adverse events in the intended patient population. It also eliminates the need for layer upon layer of metal in a situation where patients experience in-stent restenosis. Additionally it reduces the amount of metal in the coronary arteries when the patient requires multiple stents.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|